US20060127460A1 - Trombin-carrying bioabsorbable synthetic nonwoven fabric - Google Patents

Trombin-carrying bioabsorbable synthetic nonwoven fabric Download PDF

Info

Publication number
US20060127460A1
US20060127460A1 US10/534,715 US53471505A US2006127460A1 US 20060127460 A1 US20060127460 A1 US 20060127460A1 US 53471505 A US53471505 A US 53471505A US 2006127460 A1 US2006127460 A1 US 2006127460A1
Authority
US
United States
Prior art keywords
nonwoven fabric
thrombin
bioabsorbable synthetic
synthetic nonwoven
hemostatic
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
US10/534,715
Inventor
Takanori Uchida
Noriko Shinya
Hiroshi Kaetsu
Takayuki Imamura
Chikateru Nozaki
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Chemo-Sero-Therapeutic Research Institute
Original Assignee
Chemo-Sero-Therapeutic Research Institute
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority to JP2002-330677 priority Critical
Priority to JP2002330677 priority
Application filed by Chemo-Sero-Therapeutic Research Institute filed Critical Chemo-Sero-Therapeutic Research Institute
Priority to PCT/JP2003/014348 priority patent/WO2004043503A1/en
Assigned to JURIDICAL FOUNDATION THE CHEMO-SERO-THERAPEUTIC RESEARCH INSTITUTE reassignment JURIDICAL FOUNDATION THE CHEMO-SERO-THERAPEUTIC RESEARCH INSTITUTE ASSIGNMENT OF ASSIGNORS INTEREST (SEE DOCUMENT FOR DETAILS). Assignors: IMAMURA, TAKAYUKI, KAETSU, HIROSHI, NOZAKI, CHIKATERU, SHINYA, NORIKO, UCHIDA, TAKANORI
Publication of US20060127460A1 publication Critical patent/US20060127460A1/en
Application status is Abandoned legal-status Critical

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61LMETHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION, OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS, OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS, OR SURGICAL ARTICLES
    • A61L15/00Chemical aspects of, or use of materials for, bandages, dressings or absorbent pads
    • A61L15/16Bandages, dressings or absorbent pads for physiological fluids such as urine or blood, e.g. sanitary towels, tampons
    • A61L15/42Use of materials characterised by their function or physical properties
    • A61L15/44Medicaments
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/69Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit
    • A61K47/6953Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit the form being a fibre, a textile, a slab or a sheet
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61LMETHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION, OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS, OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS, OR SURGICAL ARTICLES
    • A61L15/00Chemical aspects of, or use of materials for, bandages, dressings or absorbent pads
    • A61L15/16Bandages, dressings or absorbent pads for physiological fluids such as urine or blood, e.g. sanitary towels, tampons
    • A61L15/22Bandages, dressings or absorbent pads for physiological fluids such as urine or blood, e.g. sanitary towels, tampons containing macromolecular materials
    • A61L15/26Macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds; Derivatives thereof
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61LMETHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION, OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS, OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS, OR SURGICAL ARTICLES
    • A61L15/00Chemical aspects of, or use of materials for, bandages, dressings or absorbent pads
    • A61L15/16Bandages, dressings or absorbent pads for physiological fluids such as urine or blood, e.g. sanitary towels, tampons
    • A61L15/22Bandages, dressings or absorbent pads for physiological fluids such as urine or blood, e.g. sanitary towels, tampons containing macromolecular materials
    • A61L15/32Proteins, polypeptides; Degradation products or derivatives thereof, e.g. albumin, collagen, fibrin, gelatin
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61LMETHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION, OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS, OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS, OR SURGICAL ARTICLES
    • A61L15/00Chemical aspects of, or use of materials for, bandages, dressings or absorbent pads
    • A61L15/16Bandages, dressings or absorbent pads for physiological fluids such as urine or blood, e.g. sanitary towels, tampons
    • A61L15/42Use of materials characterised by their function or physical properties
    • A61L15/64Use of materials characterised by their function or physical properties specially adapted to be resorbable inside the body
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61LMETHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION, OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS, OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS, OR SURGICAL ARTICLES
    • A61L33/00Antithrombogenic treatment of surgical articles, e.g. sutures, catheters, prostheses, or of articles for the manipulation or conditioning of blood; Materials for such treatment
    • A61L33/0005Use of materials characterised by their function or physical properties
    • A61L33/0011Anticoagulant, e.g. heparin, platelet aggregation inhibitor, fibrinolytic agent, other than enzymes, attached to the substrate
    • A61L33/0041Anticoagulant, e.g. heparin, platelet aggregation inhibitor, fibrinolytic agent, other than enzymes, attached to the substrate characterised by the choice of an antithrombatic agent other than heparin
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61LMETHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION, OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS, OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS, OR SURGICAL ARTICLES
    • A61L2300/00Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices
    • A61L2300/40Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices characterised by a specific therapeutic activity or mode of action
    • A61L2300/418Agents promoting blood coagulation, blood-clotting agents, embolising agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61LMETHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION, OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS, OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS, OR SURGICAL ARTICLES
    • A61L2400/00Materials characterised by their function or physical properties
    • A61L2400/04Materials for stopping bleeding
    • YGENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10TTECHNICAL SUBJECTS COVERED BY FORMER US CLASSIFICATION
    • Y10T442/00Fabric [woven, knitted, or nonwoven textile or cloth, etc.]
    • Y10T442/20Coated or impregnated woven, knit, or nonwoven fabric which is not [a] associated with another preformed layer or fiber layer or, [b] with respect to woven and knit, characterized, respectively, by a particular or differential weave or knit, wherein the coating or impregnation is neither a foamed material nor a free metal or alloy layer
    • Y10T442/2525Coating or impregnation functions biologically [e.g., insect repellent, antiseptic, insecticide, bactericide, etc.]
    • YGENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10TTECHNICAL SUBJECTS COVERED BY FORMER US CLASSIFICATION
    • Y10T442/00Fabric [woven, knitted, or nonwoven textile or cloth, etc.]
    • Y10T442/20Coated or impregnated woven, knit, or nonwoven fabric which is not [a] associated with another preformed layer or fiber layer or, [b] with respect to woven and knit, characterized, respectively, by a particular or differential weave or knit, wherein the coating or impregnation is neither a foamed material nor a free metal or alloy layer
    • Y10T442/2549Coating or impregnation is chemically inert or of stated nonreactance
    • Y10T442/2566Organic solvent resistant [e.g., dry cleaning fluid, etc.]

Abstract

A safe and effective hemostatic is provided. The invention relates to a bioabsorbable synthetic nonwoven fabric holding thrombin as an effective ingredient and a hemostatic comprising said bioabsorbable synthetic nonwoven fabric. The bioabsorbable synthetic nonwoven fabric holding thrombin in accordance with the present invention may be prepared by a process which comprises the steps of immersing a bioabsorbable synthetic nonwoven fabric into a solution containing thrombin and of lyophilizing the obtained nonwoven fabric. The bioabsorbable synthetic nonwoven fabric holding thrombin in accordance with the present invention allows for quicker and more effective hemostasis.

Description

    TECHNICAL FIELD
  • The present invention relates to a bioabsorbable synthetic nonwoven fabric characterized in that thrombin as an effective ingredient is held therein, a process for preparing the same and a hemostatic comprising said nonwoven fabric.
  • BACKGROUND ART
  • In the medical field, hemostatic management is very important. When the blood vessel in a living body is damaged, various coagulation factors are activated at that local area and fibrin is ultimately formed to thereby lead to hemostasis. In this process, thrombin is the most important enzyme that acts on fibrinogen so as to convert it into fibrin. Fibrinogen per se, though it is present in blood, has no hemostatic activity. It is upon the action of thrombin that the hemostatic activity is exerted. Namely, thrombin plays the most important role in a hemostatic reaction in a living body.
  • DISCLOSURE OF THE INVENTION Technical Problem to be Solved by the Invention
  • Conventional thrombin preparations are in the form of liquid or powder and hence are often washed away when applied to the bleeding area, resulting in insufficient hemostatic effect of thrombin. For obviating this disadvantage, there have been various reports concerning sheets in which thrombin is held on bioabsorbable material (e.g. WO 90/13320 and Japanese Patent Publication No. 61/59737). One of these sheets is such that thrombin derived from blood is fixed on a sheet material made of gelatin. This sheet, however, as indicated in the Examples below, failed to show a sufficient hemostatic effect and is far from practical usage due to difficulty in its manufacture and problems when actually used. There is a hemostatic in the form of gel wherein bovine gelatin is mixed with bovine thrombin but this type of a hemostatic is also disadvantageous in that it has a risk for infection such as BSE and is not easy for compression procedure when used.
  • Another type of hemostatic is a fibrin adhesive in which thrombin is combined with other coagulation factors. A fibrin adhesive, mainly consisting of thrombin and fibrinogen, is a biological tissue adhesive that exploits conversion of fibrinogen to fibrin by the action of thrombin and has been widely used in the clinical field for the purpose of adhesion, hemostasis and sealing. However, for use in e.g. surgical operation, preparing a thrombin solution and a fibrinogen solution by dissolution takes time and hence it is very inconvenient for use especially in case of emergency.
  • In consideration of such inconvenience, a fibrin adhesive which is used by directly pressing to the bleeding area with a sheet is also in a practical usage. However, the currently available sheet type adhesive is not ideal since it consists of equine collagen as a basic material together with thrombin derived from bovine, i.e. material derived from non-human animal species, and hence there is a possibility that an antibody against heterologous proteins is elicited and a risk of zoonotic infections such as prion disease. Thus, the currently available topical hemostatics are not satisfactorily easy in handling and safe.
  • In order to solve the problems mentioned above, there is a need for a hemostatic comprising a coagulation factor that is derived from human and is free from an infectious agent, said hemostatic being in the form of a sheet made of a material that is strictly selected and devised for full achievement of a hemostatic effect and is safe to a living body.
  • Means for Solving the Problems
  • In view of the above-mentioned various problems, the present inventors have carried out intensive investigation and completed the present invention concerning a topical hemostatic. Thus, selecting a bioabsorbable synthetic material processed in the form of a nonwoven fabric among various bioabsorbable material, the present invention relates to a bioabsorbable synthetic nonwoven fabric holding thrombin as an effective ingredient for hemostasis, a process for preparation thereof, and a hemostatic comprising said nonwoven fabric.
  • More Efficacious Effects than Prior Art
  • The bioabsorbable synthetic nonwoven fabric holding thrombin in accordance with the present invention has excellent properties as listed below and hence is an ideal topical hemostatic.
    • (1) It has an excellent hemostatic effect;
    • (2) It can be handled with ease upon emergency;
    • (3) It is highly safe;
    • (4) It is absorbed with a lapse of time;
    • (5) It shows an excellent elasticity and flexibility;
    • (6) It enables for hemostasis at a broad area;
    • (7) It induces a slight or no inflammation reaction.
  • Accordingly, the present invention provides for a hemostatic comprising a bioabsorbable synthetic nonwoven fabric which allows for hemostasis with safe in such a surgical operation that requires for sealing of tissues in various fields of the operation.
  • BEST MODE FOR CARRYING OUT THE INVENTION
  • The bioabsorbable synthetic nonwoven fabric used in the present invention may be any nonwoven fabric made of a bioabsorbable synthetic fiber. The nonwoven fabric of the present invention has preferably appropriate flexibility to ensure that it may surely coat any affected area. For example, a synthetic fiber that may form such a nonwoven fabric includes polyglycolic acid, polylactic acid, or a copolymer of glycolic acid with lactic acid, etc., which may be used after processing into a nonwoven fabric. Among these, a bioabsorbable synthetic nonwoven fabric which is prepared from polyglycolic acid by processing into a nonwoven fabric is the most preferable material for the purpose of the present invention.
  • The nonwoven fabric of the present invention may be in any shape but preferably in the form of a sheet in view of versatility to various applications.
  • For thrombin, both thrombin derived from human blood and a recombinant thrombin obtained by the recombinant DNA technique may be used. In addition to thrombin, a pharmaceutically acceptable stabilizer and additive may also be added. Examples of such stabilizer and additive include, for instance, albumin, polyethylene glycol, arginine, sodium hyaluronate, glycerol, mannitol and calcium chloride etc.
  • The bioabsorbable synthetic nonwoven fabric holding thrombin in accordance with the present invention may be manufactured, for instance, as described below.
  • Thrombin is dissolved in a saline or a buffer and thereto is further added optionally albumin, polyethylene glycol, arginine, hyaluronic acid, glycerol, mannitol, or calcium chloride etc. as a stabilizer or an additive. A bioabsorbable synthetic nonwoven fabric is then immersed into the solution, frozen at −80° C. for 2 hours and lyophilized to give a desired product.
  • The bioabsorbable nonwoven fabric holding thrombin according to the present invention may be pressed onto a bleeding area to prevent outflow of blood through pressure and besides thrombin contained in the sheet instantly reacts with fibrinogen in the blood to render fibrinogen be converted to fibrin to thereby achieve a hemostatic effect at the local area. The formed fibrin may adhere to the surrounding tissues.
  • A bioabsorbable nonwoven fabric made of polyglycolic acid has already been used for a medical purpose and its safety has been proved as being absorbed into the living body and being decomposed into water and carbon dioxide.
  • INDUSTRIAL APPLICABILITY
  • As such, the bioabsorbable nonwoven fabric holding thrombin according to the present invention may easily and quickly be applied to topical bleeding and allows for efficient hemostasis through both pressure and a blood coagulation reaction. Besides, since every material used in said bioabsorbable nonwoven fabric is safe to the living body, it may be used in a clinical situation without care.
  • The present invention is explained in more detail by means of the following Examples but should not be construed to be limited thereto.
  • EXAMPLE 1 Preparation of Recombinant Thrombin
  • A recombinant thrombin was prepared as described in Japanese Patent Application No. 2001/206,919. Briefly, animal cells to which a human prethrombin gene is introduced are cultured and prethrombin is then purified from the resulting culture medium. On the other hand, ecarin is purified from a culture medium of animal cells into which ecarin gene is introduced. Prethrombin is activated by ecarin as obtained to thereby provide thrombin that may be purified.
  • EXAMPLE 2 Preparation of Sheet Holding Thrombin
  • A sheet holding thrombin in accordance with the present invention was prepared by the process as described below.
  • To a solution containing 0.001 to 0.01% sodium hyaluronate (nacalai tesque; 18237-41) or 0.5 to 2% glycerol (nacalai tesque; 17018) are added mannitol (nacalai tesque; 21303) at a final concentration of 0.5 to 1.5% and 40 mM calcium chloride and subsequently the recombinant thrombin at a final concentration of 1000 U/mL. The solution is added dropwise to a bioabsorbable synthetic nonwoven fabric made of polyglycolic acid (3 cm×3 cm; Neoveil, Gunze Limited, thickness 0.15 mm) at 0.05 mL/cm2. The sheet, after being frozen at −80° C. for 2 hours and lyophilized, is used as a sample of a sheet holding recombinant thrombin. Similarly, a sheet holding thrombin derived from blood is prepared using thrombin derived from human blood instead of the recombinant thrombin.
  • As a control, a bioabsorbable synthetic nonwoven fabric not treated with thrombin, a hemostatic sponge made of gelatin prepared as described in Examples of WO 90/13320 and a commercially available fibrin adhesive in sheet were used.
  • Group 1: Sheet Holding Thrombin Derived from Blood
  • A sheet was used where thrombin derived from human blood was held in a nonwoven fabric made of polyglycolic acid at 50 U/cm2.
  • Group 2: Sheet Holding Recombinant Thrombin A sheet was used where a recombinant thrombin was held in a nonwoven fabric made of polyglycolic acid at 50 U/cm2.
  • Group 3: Sheet with no Thrombin
  • A sheet was used where a nonwoven fabric made of polyglycolic acid was treated as in Group 1 with no thrombin.
  • Group 4: Hemostatic Sponge with Fixed Thrombin
  • A hemostatic sponge made of gelatin containing thrombin derived from human blood was used that was prepared as described in Examples of WO 90/13320 (Spongostan, Johnson & Johnson K. K.).
  • Group 5: Fibrin Adhesive in Sheet
  • A fibrin adhesive in sheet where components of a fibrin adhesive are fixed on a collagen sheet (TachoComb, Torii Pharmaceutical Co., Ltd.) was used wherein components such as fibrinogen and thrombin were fixed by lyophilization on one side of a sponge sheet made of equine collagen.
  • EXAMPLE 3: Test for Hemostasis in Exudative Bleeding
  • Rabbit was used as an animal model for assessing hemostasis. Rabbit was subject to abdominal section and a part of the liver was excised, to which bleeding area each hemostatic of the groups as prepared in Example 2 was applied for a whole area of the wound and was pressed for a minute. Assessment used was as indicated below.
  • (1) Rabbit was subject to abdominal section under anesthesia with Nembutal.
  • (2) Heparin was intravenously administered at 300 U/kg.
  • (3) The surface of the right lobe, the inner left lobe or the outer left lobe of the liver was excised in a shape of circle of 1.5 cm diameter with thickness of 4 mm.
  • (4) Bleeding from the excised wound was absorbed with gauze for 10 seconds and weighed. An amount of bleeding after generation of the excised wound was about 0.50 g.
  • (5) Attempt to cease bleeding was done with various hemostatic means as mentioned above. Each treatment was conducted without avascularization but with blood flowing out.
  • (6) Bleeding for 5 minutes, including the time required for the hemostatic treatment, was absorbed with gauze and weighed. When bleeding from the wound surface was observed after 5 minutes, the hemostatic treatment and the weighing of bleeding were repeated.
  • (7) The hemostatic treatment was repeated for at most four times and assessment was made with a frequency of the hemostatic treatment needed for hemostasis and a total weight of bleeding from the initiation of the hemostatic treatment up till hemostasis (Table 1).
    TABLE 1
    No. of cases in which
    hemostasis was achieved with Total bleeding
    each of hemostatic treatment after hemostatic
    Group 1st 2nd 3rd 4th treatments/g
    1 7 1 0 0 0.51 ± 0.31
    2 7 1 0 0 0.34 ± 0.15
    3 2 3 3 0 2.03 ± 0.95
    4 0 2 4  2* 6.28 ± 1.67
    5 0 4 1  3* 6.70 ± 2.64

    *Even after the fourth hemostatic treatment, cases were observed where hemostasis was not possible.
  • As shown in Table 1, the sheet holding thrombin of the present invention was found to exhibit a more excellent hemostatic effect in both thrombin derived from blood (Group 1) and a recombinant thrombin (Group 2) than that of the control sheets. With a nonwoven fabric alone with no thrombin treatment (Group 3), a hemostatic effect was scarcely observed but was even higher than that of the hemostatic sponge made of gelatin with fixed thrombin (Group 4) as described in WO 90/13320. This indicates that, among the known bioabsorbable material, a bioabsorbable nonwoven fabric used in the present invention as a substrate is the most suitable material for use in hemostasis. It was further revealed that holding thrombin in this nonwoven fabric allowed for quicker and more effective hemostasis. Besides, as is clear from the results of the comparative test, the fibrin adhesive in sheet where collagen is used as a substrate (Group 5) showed far less hemostatic effect as compared to the sheet holding thrombin of the present invention.

Claims (9)

1. A bioabsorbable synthetic nonwoven fabric holding thrombin as an effective ingredient.
2. The bioabsorbable synthetic nonwoven fabric according to claim 1, wherein said bioabsorbable synthetic nonwoven fabric is made of a material selected from the group consisting of polyglycolic acid, polylactic acid and a copolymer of glycolic acid and lactic acid.
3. The bioabsorbable synthetic nonwoven fabric according to claim 2, wherein said material is polyglycolic acid.
4. The bioabsorbable synthetic nonwoven fabric according to claim 1, wherein the thrombin is thrombin derived from human blood or a recombinant human thrombin produced by a recombinant DNA technique.
5. A hemostatic that uses the bioabsorbable synthetic nonwoven fabric as set forth in claim 1.
6. A process for preparing a bioabsorbable synthetic nonwoven fabric holding thrombin which comprises the steps of immersing a bioabsorbable synthetic nonwoven fabric into a solution containing thrombin and of lyophilizing the obtained nonwoven fabric.
7. The process according to claim 6, wherein said bioabsorbable synthetic nonwoven fabric is made of a material selected from the group consisting of polyglycolic acid, polylactic acid and a copolymer of glycolic acid and lactic acid.
8. The process according to claim 7, wherein said material is polyglycolic acid.
9. The process according to claim 6, wherein the thrombin is thrombin derived from human blood or a recombinant human thrombin produced by a recombinant DNA technique.
US10/534,715 2002-11-14 2003-11-12 Trombin-carrying bioabsorbable synthetic nonwoven fabric Abandoned US20060127460A1 (en)

Priority Applications (3)

Application Number Priority Date Filing Date Title
JP2002-330677 2002-11-14
JP2002330677 2002-11-14
PCT/JP2003/014348 WO2004043503A1 (en) 2002-11-14 2003-11-12 Thrombin-carrying bioabsorbable synthetic nonwoven fabric

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US11/941,779 US8043629B2 (en) 2002-11-14 2007-11-16 Bioabsorbable synthetic nonwoven fabric holding thrombin

Related Child Applications (1)

Application Number Title Priority Date Filing Date
US11/941,779 Continuation US8043629B2 (en) 2002-11-14 2007-11-16 Bioabsorbable synthetic nonwoven fabric holding thrombin

Publications (1)

Publication Number Publication Date
US20060127460A1 true US20060127460A1 (en) 2006-06-15

Family

ID=32310601

Family Applications (2)

Application Number Title Priority Date Filing Date
US10/534,715 Abandoned US20060127460A1 (en) 2002-11-14 2003-11-12 Trombin-carrying bioabsorbable synthetic nonwoven fabric
US11/941,779 Active 2025-04-18 US8043629B2 (en) 2002-11-14 2007-11-16 Bioabsorbable synthetic nonwoven fabric holding thrombin

Family Applications After (1)

Application Number Title Priority Date Filing Date
US11/941,779 Active 2025-04-18 US8043629B2 (en) 2002-11-14 2007-11-16 Bioabsorbable synthetic nonwoven fabric holding thrombin

Country Status (8)

Country Link
US (2) US20060127460A1 (en)
EP (1) EP1563856A4 (en)
JP (1) JPWO2004043503A1 (en)
KR (1) KR20050084954A (en)
CN (1) CN100356987C (en)
AU (1) AU2003280730B2 (en)
CA (1) CA2504812A1 (en)
WO (1) WO2004043503A1 (en)

Cited By (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20060257458A1 (en) * 2004-10-20 2006-11-16 Gorman Anne J Reinforced absorbable multilayered hemostatis wound dressing
US20090226530A1 (en) * 2008-01-15 2009-09-10 Lassner Peter K Powdered protein compositions and methods of making same
US20090246238A1 (en) * 2004-10-20 2009-10-01 Anne Jessica Gorman Reinforced absorbable multilayered hemostatic wound dressing
US20150151020A1 (en) * 2012-05-14 2015-06-04 Teijin Limited Formed sheet product and hemostatic material

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20060127460A1 (en) 2002-11-14 2006-06-15 Juridical Foundation The Chemosero-Therapeutic Research Institute Trombin-carrying bioabsorbable synthetic nonwoven fabric
JP2006345745A (en) * 2005-06-15 2006-12-28 Juntendo Method for creating hepatic carcinoma non-human animal model
US9149557B2 (en) 2008-04-16 2015-10-06 The Chemo-Sero-Therapeutic Research Institute Process for preparing bioabsorbable sheet preparation holding thrombin
KR101866571B1 (en) * 2012-06-29 2018-06-11 코오롱인더스트리 주식회사 Biodegradable Non-woven Web, Method for Manufacturing The Same, and Blood Filter Using The Same
CN104027846A (en) * 2014-06-20 2014-09-10 东华大学 Non-woven material reinforced tissue engineering composite three-dimensional scaffold and preparation method thereof

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6056970A (en) * 1998-05-07 2000-05-02 Genzyme Corporation Compositions comprising hemostatic compounds and bioabsorbable polymers
US20060051340A1 (en) * 2003-01-20 2006-03-09 Juridical Foundation The Chemo-Sero-Therapeutic Research Institute Hemostatic materials

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS54104687A (en) * 1978-02-01 1979-08-17 Unitika Ltd Novel injury protecting material
US4265233A (en) * 1978-04-12 1981-05-05 Unitika Ltd. Material for wound healing
JPH0115306B2 (en) * 1981-08-28 1989-03-16 Unitika Ltd
NZ205863A (en) * 1982-10-18 1985-09-13 Johnson & Johnson Prod Inc Absorbable haemostatic material containing lactide and glycolide homopolymers and copolymers
JPH0518579B2 (en) * 1986-10-09 1993-03-12 Gunze Kk
DK223389D0 (en) * 1989-05-05 1989-05-05 Ferrosan As Saarsvamp
GB9503750D0 (en) 1995-02-24 1995-04-12 Common Services Agency Thrombin preparation
JP3526487B2 (en) * 1995-05-08 2004-05-17 株式会社伊垣医療設計 Medical suture material
JP3795100B2 (en) * 1995-05-08 2006-07-12 グンゼ株式会社 Medical suture material
JPH11309151A (en) * 1998-04-30 1999-11-09 Hoechst Marion Roussel Kk Surgical suturing device
WO1999059647A1 (en) * 1998-05-19 1999-11-25 The American National Red Cross Hemostatic sandwich bandage
US20060127460A1 (en) 2002-11-14 2006-06-15 Juridical Foundation The Chemosero-Therapeutic Research Institute Trombin-carrying bioabsorbable synthetic nonwoven fabric

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6056970A (en) * 1998-05-07 2000-05-02 Genzyme Corporation Compositions comprising hemostatic compounds and bioabsorbable polymers
US20060051340A1 (en) * 2003-01-20 2006-03-09 Juridical Foundation The Chemo-Sero-Therapeutic Research Institute Hemostatic materials

Cited By (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20060257458A1 (en) * 2004-10-20 2006-11-16 Gorman Anne J Reinforced absorbable multilayered hemostatis wound dressing
US20080260810A1 (en) * 2004-10-20 2008-10-23 Guanghui Zhang Hemostat
US20090246238A1 (en) * 2004-10-20 2009-10-01 Anne Jessica Gorman Reinforced absorbable multilayered hemostatic wound dressing
US9358318B2 (en) 2004-10-20 2016-06-07 Ethicon, Inc. Method of making a reinforced absorbable multilayered hemostatic wound dressing
US9439997B2 (en) 2004-10-20 2016-09-13 Ethicon, Inc. Reinforced absorbable multilayered hemostatis wound dressing
US20130136781A1 (en) * 2005-10-17 2013-05-30 Anne Jessica Gorman Reinforced absorbable multilayered hemostatic wound dressing
US20090226530A1 (en) * 2008-01-15 2009-09-10 Lassner Peter K Powdered protein compositions and methods of making same
US9610301B2 (en) * 2008-01-15 2017-04-04 Abbvie Deutschland Gmbh & Co Kg Powdered protein compositions and methods of making same
US20150151020A1 (en) * 2012-05-14 2015-06-04 Teijin Limited Formed sheet product and hemostatic material

Also Published As

Publication number Publication date
AU2003280730A1 (en) 2004-06-03
CN100356987C (en) 2007-12-26
AU2003280730B2 (en) 2010-04-29
KR20050084954A (en) 2005-08-29
EP1563856A4 (en) 2008-02-27
CN1711111A (en) 2005-12-21
EP1563856A1 (en) 2005-08-17
US20080286347A1 (en) 2008-11-20
WO2004043503A1 (en) 2004-05-27
CA2504812A1 (en) 2004-05-27
US8043629B2 (en) 2011-10-25
JPWO2004043503A1 (en) 2006-03-09

Similar Documents

Publication Publication Date Title
US5883078A (en) Hemostyptic and tissue adhesive
AU2007334394B2 (en) Gelatin-transglutaminase hemostatic dressings and sealants
KR101487840B1 (en) Hemostatic textile
NL192665C (en) Tissue Adhesive Containing factor XIII and fibrinogen.
JP4223548B2 (en) Supplement or non-supplemented tissue sealant, their preparation and use
CA2131316C (en) A thrombin blood fraction for use in a medical procedure
EP1731175B1 (en) Hemostatic cross-linked dextran beads useful for rapid blood coagulation and hemostatis
KR100830294B1 (en) Carrier with Solid Fibrinogen and Solid Thrombin
US4238480A (en) Method for preparing an improved hemostatic agent and method of employing the same
US20030133967A1 (en) Multilayer collagen matrix for tissue reconstruction
US4404970A (en) Hemostatic article and methods for preparing and employing the same
EP0172710B1 (en) Hemostatic agent
AU674126B2 (en) Tissue treatment composition comprising fibrin or fibrinogenand biodegradable and biocompatible polymer
US20030147878A1 (en) Tissue treatment compositions
AU2005295365B2 (en) Absorbable hemostat
AU726163B2 (en) Hemostatic sponge based on collagen
US6117425A (en) Supplemented and unsupplemented tissue sealants, method of their production and use
US4997425A (en) Wound dressing
AU2004245086B2 (en) Compositions for repairing and regenerating human dura mater
AU2001297782B2 (en) Expandable foam-like biomaterials and methods
DK2442835T3 (en) Styptic sponge
ES2202306T3 (en) Fibrin sealant compositions and methods for their use.
US6486377B2 (en) Flexible wound covering based on fibrin and process for its production
US6197325B1 (en) Supplemented and unsupplemented tissue sealants, methods of their production and use
EP0726749B1 (en) Hemostatic patch

Legal Events

Date Code Title Description
AS Assignment

Owner name: JURIDICAL FOUNDATION THE CHEMO-SERO-THERAPEUTIC RE

Free format text: ASSIGNMENT OF ASSIGNORS INTEREST;ASSIGNORS:UCHIDA, TAKANORI;SHINYA, NORIKO;KAETSU, HIROSHI;AND OTHERS;REEL/FRAME:016633/0151

Effective date: 20050414

STCB Information on status: application discontinuation

Free format text: ABANDONED -- FAILURE TO RESPOND TO AN OFFICE ACTION